In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
GEN News
|
June 1, 2026
Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives
First patient dosed in Phase II AMETHYST trial days after Sobi announces positive Phase III data for pozdeutinurad, which like…
For more
Fierce Pharma
|
May 29, 2026
After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 lung cancer market,…
For more
Longevity.Technology
|
May 19, 2026
‘Rebuilding the human immune system is possible’
As immunosenescence drives systemic disease, banked bone marrow could scale from a transplant tool into healthspan infrastructure. Bone marrow transplantation…
For more
South Florida Business Journal
|
May 8, 2026
European company to acquire Miami pharma business for $4.1 billion
The deal is part of a wider trend of acquisitions in this emerging industry….
For more
Bloomberg
|
May 7, 2026
Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion
Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build…
For more
The Bio Report
|
May 6, 2026
Addressing Treatment Gaps in Gout
Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source…
For more
Life Science Leader
|
April 28, 2026
Implementing A New CEO Strategy With NervGen’s Adam Rogers, M.D. And Rich Macary
On this week’s episode of the Business of Biotech, NervGen Pharma Corp. leaders Adam Rogers, M.D., and Rich Macary talk…
For more
Reuters
|
April 22, 2026
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics (ACTU) with chemotherapy were alive after…
For more
Labiotech
|
April 17, 2026
Therapy for brain injuries in infants bags funding: is the first HIE drug on the way?
The fifth leading cause of death globally in children under the age of five, HIE is a type of brain damage…
For more
Inside Precision Medicine
|
April 15, 2026
It’s HAMMR Time: Duracyte Launches with “Living Pharmacy” Platform
The Houston startup is advancing its Hybrid Advanced Molecular Manufacturing Regulator, an implantable bioreactor that produces biologic drugs in patients….
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
